利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.018 秒)

    2-amino-7-hydroxytetralin carboxylalkyl ethers
    1.
    发明授权
    2-amino-7-hydroxytetralin carboxylalkyl ethers 失效
    2-氨基-7-羟基四氢萘基羧基烷基醚

    公开(公告)号：US5312961A

    公开(公告)日：1994-05-17

    申请号：US905483

    申请日：1992-06-29

    申请人： Umberto Guzzi ,  Roberto Cecchi ,  Luciano Manara

    发明人： Umberto Guzzi ,  Roberto Cecchi ,  Luciano Manara

    IPC分类号： A61K31/135 ,  A61K31/165 ,  A61K31/22 ,  C07C217/74 ,  C07C101/72

    CPC分类号： A61K31/135 ,  A61K31/165 ,  A61K31/22 ,  C07C217/74 ,  C07C2102/10

    摘要： The invention relates to 2-amino-7-hydroxytetralin carboxyalkyl ethers of formula ##STR1## wherein Alk represents a straight or branched (C.sub.3 -C.sub.5)alkylene group, and R is hydrogen or (C.sub.1 -C.sub.4)alkyl, useful as starting materials in the synthesis of 7-substituted phenylethanolaminotetralins of formula (XII) ##STR2## wherein X represents hydrogen, halogen, (C.sub.1 -C.sub.4)alkyl, or trifluoromethyl which are useful as spasmolytics and anti-glaucoma agents.The new 7-substituted phenylethanolaminotetralins (XII) as well as the intermediates in the preparation of the compounds (I), the N-protected 2-amino-7-hydroxytetralin carboxyalkyl ethers, are also claimed.

    摘要翻译： 本发明涉及式（I）的2-氨基-7-羟基四氢萘羧酸烷基醚，其中Alk表示直链或支链（C3-C5）亚烷基，R是氢或（C1-C4）烷基，可用作 合成式（XII）的7-取代苯乙醇氨基十氢化萘（XII）的原料，其中X代表氢，卤素，（C1-C4）烷基或三氟甲基，其可用作解聚物和抗青光眼剂。 还要求保护新的7-取代苯乙醇氨基十氢化萘（XII）以及化合物（I），N-保护的2-氨基-7-羟基四氢萘烷羧基烷基醚的制备中的中间体。

    Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
    3.
    发明授权
    Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same 失效
    苯氧基丙醇胺，其制备方法和含有它们的药物组合物

    公开(公告)号：US06649627B1

    公开(公告)日：2003-11-18

    申请号：US09719640

    申请日：2001-03-26

    申请人： Roberto Cecchi ,  Tiziano Croci ,  Umberto Guzzi ,  Eric Marsault

    发明人： Roberto Cecchi ,  Tiziano Croci ,  Umberto Guzzi ,  Eric Marsault

    IPC分类号： A61K31445

    CPC分类号： C07D303/22 ,  C07D307/42 ,  C07D401/04 ,  C07D401/06 ,  C07D405/14

    摘要： The invention concerns compounds of formula (Ia) wherein R1a represents hydrogen, an —S(O)z —(C1-C4)Alk group, a —CO(C1-C4)Alk group, an —NHSO2—(C1-C4)Alk group, an NCHl (C1-C4) Alk group, a 2-furyl group or a halogen; R2 represents hydrogen or a (C1-C4)Alk group, a (C1-C4) alkoxyl group, a halogen, —COOH, —COO(C1-C4)Alk, —CN, —CONR3R4, —NO2, —SO2NH2, —NHSO2(C1-C4)Alk; m and n are independently 0, 1 or 2; R3 and R4 independently represent hydrogen or a (C1-C4)Alk group; Z is 1 or 2 and their salts or solvates, the pharmaceutical compositions that contain them, the process for their preparation, and intermediate synthesis products.

    摘要翻译： 本发明涉及式（Ia）化合物，其中R 1a表示氢，-S（O）z - （C 1 -C 4）Alk基，-CO（C 1 -C 4）Alk基，-NHSO 2 - （C 1 -C 4） 基团，NCH1（C1-C4）Alk基团，2-呋喃基或卤素; R2表示氢或（C1-C4）Alk基团，（C1-C4）烷氧基，卤素，-COOH， COO（C1-C4）Alk，-CN，-CONR3R4，-NO2，-SO2NH2，-NHSO2（C1-C4）Alk; m和n分别为0,1或2; R3和R4独立地表示氢或（C1 -C4）Alk基; Z为1或2及其盐或溶剂化物，含有它们的药物组合物，其制备方法和中间合成产物。

    Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same
    10.
    发明授权
    Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same 有权

    公开(公告)号：US07622460B2

    公开(公告)日：2009-11-24

    申请号：US12144843

    申请日：2008-06-24

    申请人： Philippe R. Bovy ,  Roberto Cecchi ,  Gilles Courtemanche ,  Tiziano Croci ,  Ambrogio Oliva ,  Nunzia Viviani

    发明人： Philippe R. Bovy ,  Roberto Cecchi ,  Gilles Courtemanche ,  Tiziano Croci ,  Ambrogio Oliva ,  Nunzia Viviani

    IPC分类号： A61K31/553 ,  C07D263/54 ,  C07D267/02 ,  C07C311/01

    摘要： The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl group or an —NHSO2phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group; R1 represents a hydrogen atom or a (C1-C4)alkyl group, a —CO(C1-C4)alkyl group, a phenyl-(C1-C4)alkyl group or a —COphenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C1-C4)alkoxy group; R2 is a hydrogen atom or an —SO2(C1-C4)alkyl group, an —SO2phenyl-(C1-C4)alkyl group or an —SO2phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C1-C4)alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R3 represents a hydrogen or halogen atom, a (C1-C6)alkyl group, a (C1-C4)alkoxy group, a —COO(C1-C4)alkyl group, a —CO(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl groups, —NO2, —CN, —CONR4R5, —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R4 and R5 represent, independently, a hydrogen atom, a phenyl, a (C1-C4)alkyl group or a phenyl-(C1-C4)alkyl group or R4 and R5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.